SynthesisInfluenza and other respiratory viruses2023
Systematic literature review of the signs and symptoms of respiratory syncytial virus.
Synthesis in Influenza and other respiratory viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Programmed cell death in human respiratory syncytial virus infection.Frontiers in cellular and infection microbiology · 2025Pooled it
- Systematic literature review of the signs and symptoms of respiratory syncytial virus.Influenza and other respiratory viruses · 2023Pooled it
- Efficacy and safety of inhaled ambroxol hydrochloride solution in patients with lower respiratory tract infectious diseases: a randomized, double-blind, placebo-controlled, multicentre clinical trial.BMC infectious diseases · 2025Trial
- Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Article
- Evidence-to-Recommendation Framework for 2026 ACE Clinical Guideline on upper respiratory tract infections - rational antimicrobial use.Singapore medical journal · 2026Article
- Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Clinical presentation and hospitalisation risk of RSV in primary care among children younger than 5 years in Italy in four seasons between 2019 and 2023: a multicentre prospective cohort study.The Lancet regional health. Europe · 2026Article
- Age-related pharyngeal microbiome and host transcriptomic signatures underlying fever responses in RSV bronchiolitis.Virologica Sinica · 2026Article
- New Tools Against Old Enemies: Respiratory Syncytial Virus (RSV) in Older Adults. A Narrative Review.Farmaceuticos comunitarios · 2026Article
- Identification of key clinical features for pediatric respiratory syncytial virus infection using machine learning.BMC pediatrics · 2026Article
- Comparison of Hospitalization Rates and Clinical Features Between Boys and Girls With Respiratory Syncytial Virus Infection.Influenza and other respiratory viruses · 2026Article
- Streamlining protocols for the establishment of a physical biobank of respiratory viruses in the Philippines.Journal of translational medicine · 2026Article
- AI-driven early infectious disease detection in Dutch primary care using BERT and ERNIE.NPJ digital medicine · 2025Article
- The top 100 most cited articles on pediatric respiratory syncytial virus pneumonia over the last 30 years: a bibliometric analysis.Tropical medicine and health · 2025Article
- Respiratory Syncytial Virus Epidemiology and Clinical Characteristics among Young Children Hospitalized in Sierra Leone.The American journal of tropical medicine and hygiene · 2025Article
- Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Respiratory Syncytial Virus and COVID-19 in Hospitalized Adults in Spain: Clinical, Radiological Features and Antimicrobial Use.Immunity, inflammation and disease · 2025Article
- Respiratory Syncytial Virus Infection in Children with Acute Lymphoblastic Leukemia (ALL): A Contemporary Emerging and Struggling Clinical Event.Pediatric reports · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is responsible for over 30 million lower respiratory tract infections (LRTIs) and 3 million hospitalizations worldwide each year. Despite the risk RSV poses to young children, older adults, and individuals with comorbidities or suppressed immunity, there is limited understanding of RSV symptom presentation across these at-risk groups, and there is no vaccine for RSV. We conducted two systematic literature reviews (SLRs) of studies that document signs and symptoms (S&S) of RSV in (1) children aged ≤5 years and (2) immunocompromised adolescents and adults, and adults at high risk for severe RSV due to age or comorbidities. Symptom duration and hospital length of stay (LOS) were explored. Electronic database searches were performed following PRISMA guidelines. Studies captured RSV S&S across community and hospital settings. Clinicians and caregivers reported (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.